Passage BIO (PASG) Non-Current Assets (2019 - 2026)
Passage BIO (PASG) posted quarterly Non-Current Assets of $1.7 million for Q1 2026, down 91.1% year-over-year from $19.3 million in Q1 2025, and down 88.15% quarter-over-quarter from $14.5 million in Q4 2025.
Passage BIO (PASG) Non-Current Assets (2019 - 2026) Analysis & Trends
Passage BIO's Non-Current Assets history runs 8 years deep, the most recent figure standing at $1.7 million for Q1 2026.
- In Q1 2026, Non-Current Assets fell 91.1% year-over-year to $1.7 million; the TTM figure through Mar 2026 stood at $53.6 million (down 45.28% YoY), while the FY2025 annual figure was $14.5 million, down 38.47% from the prior year.
- Non-Current Assets for Q1 2026 stood at $1.7 million, down from $14.5 million in the prior quarter.
- The five-year high for Non-Current Assets was $50.2 million in Q1 2022, with the low at $1.7 million in Q1 2026.
- The 5-year median for Non-Current Assets is $32.2 million (2024), against an average of $30.9 million.
- The sharpest annual moves came in 2022 and 2026: Non-Current Assets soared 253.11% in 2022, then slumped 91.1% in 2026.
- Passage BIO's Non-Current Assets stood at $46.5 million in 2022, then fell by 29.93% to $32.6 million in 2023, then decreased by 27.59% to $23.6 million in 2024, then tumbled by 38.47% to $14.5 million in 2025, then plunged by 88.15% to $1.7 million in 2026.
- Business Quant data shows PASG's Non-Current Assets at $1.7 million in Q1 2026, $14.5 million in Q4 2025, and $18.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 18.06 Bn |
| 10 | Passage BIO | 13.99 Mn | 13.99 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.72 Mn |
| Dec 31, 2025 | 14.52 Mn |
| Sep 30, 2025 | 18.43 Mn |
| Jun 30, 2025 | 18.88 Mn |
| Mar 31, 2025 | 19.34 Mn |
| Dec 31, 2024 | 23.60 Mn |
| Sep 30, 2024 | 24.54 Mn |
| Jun 30, 2024 | 30.39 Mn |
| Mar 31, 2024 | 32.24 Mn |
| Dec 31, 2023 | 32.59 Mn |
| Sep 30, 2023 | 33.55 Mn |
| Jun 30, 2023 | 40.07 Mn |
| Mar 31, 2023 | 41.62 Mn |
| Dec 31, 2022 | 46.51 Mn |
| Sep 30, 2022 | 47.53 Mn |
| Jun 30, 2022 | 48.84 Mn |
| Mar 31, 2022 | 50.22 Mn |
| Dec 31, 2021 | 30.01 Mn |
| Sep 30, 2021 | 24.47 Mn |
| Jun 30, 2021 | 20.69 Mn |